Phio Pharmaceuticals (then RXi Pharmaceuticals) — Q2 2016 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2016. The filing describes RXi as a clinical-stage RNAi company developing RXI-109 and Samcyprone; it reports a 1-for-10 reverse stock split effective April 18, 2016.
Financial performance and liquidity
Amounts below are in thousands of dollars, except per-share data. Revenue was minimal, and the company remained loss-making with no product sales.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $9 | $0 | $19 | $34 |
| Research and development expense | $1,339 | $1,361 | $2,644 | $3,468 |
| General and administrative expense | $885 | $804 | $1,835 | $1,677 |
| Operating loss | $(2,215) | $(2,165) | $(4,460) | $(5,111) |
| Net loss | $(2,212) | $(2,166) | $(4,443) | $(5,111) |
| Net loss per common share | $(0.34) | $(0.50) | $(0.68) | $(1.56) |
At June 30, cash and cash equivalents were $3.832 million, short-term investments $2.000 million, and restricted cash $50,000. Total current assets were $6.359 million versus current liabilities of $1.553 million; total assets were $6.521 million and stockholders’ equity $4.968 million. No debt is reported in the supplied filing text. First-half operating cash use was $4.785 million, compared with $3.772 million in 2015; investing activities provided $3.500 million, primarily from net maturities of short-term investments. There were no financing cash flows in the first half of 2016. The filing gives no meaningful gross or operating margin discussion given the negligible revenue and operating losses.
Material changes versus the prior period
- First-half revenue fell $15,000, or 44%, as the National Cancer Institute grant completed in 2015. 2016 revenue came from license agreements with MirImmune and Thera Neuropharma; Q2 revenue included the reported value of equity and a warrant received under the Thera agreement.
- First-half R&D expense declined 24%, mainly because 2015 included Samcyprone license-related fees and retinal-scarring toxicology work, and because stock compensation decreased. Q2 R&D was broadly flat year over year.
- First-half G&A increased 9%, largely due to professional, legal, and proxy-related expenses associated with the special meeting and reverse split, partly offset by lower stock compensation.
- First-half net loss improved to $4.443 million from $5.111 million, while operating cash use increased by $1.013 million. Cash, cash equivalents, and short-term investments declined to $5.832 million from $10.617 million at year-end 2015.
Outlook, risks, and unusual items
- Going concern and funding: Management states that current resources may not fund operations for at least the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern. It expects to seek capital through securities sales or strategic opportunities; financing may dilute shareholders, and success is not assured.
- Programs and outlook: RXI-109 was in a Phase 2 dermal-scarring study and a Phase 1/2 retinal-scarring study; Samcyprone was in a Phase 2a wart study, with full enrollment expected before year-end 2016. The company expected R&D spending to increase as discovery, preclinical, and clinical work expanded. These are forward-looking expectations, not guarantees.
- Other development plans: The company was developing topical delivery approaches for RXI-231 and RXI-185 and planned functional and safety testing to support human testing of one consumer-health target by the end of 2016.
- Equity and listing: The reverse split restored compliance with Nasdaq’s minimum bid-price requirement. Warrants covering 1,256,502 shares at $4.55 expired July 2, 2016. Subsequent to quarter-end, RXi sold 35,000 shares to Lincoln Park Capital for approximately $82,000 net proceeds.
- Contingencies and controls: The filing reports no legal proceedings and no material accrued liabilities for ordinary-course indemnification obligations. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
- Disclosure inconsistency to note: The Thera license note’s stated investment and warrant carrying values do not readily reconcile with the balance sheet’s $27,000 of other assets and the fair-value table’s $5,000 warrant value. The filing text does not provide a clear reconciled value.
Most important facts for investors to verify
- Available cash runway, current spending plans, and whether additional financing or a strategic transaction was secured after the filing.
- Clinical-trial enrollment, results, safety, regulatory progress, and actual timing for RXI-109 and Samcyprone.
- The Thera investment and warrant accounting and the apparent discrepancy among the note, balance sheet, and fair-value table.
- Post-quarter share issuance, LPC facility usage, warrant expirations, and resulting dilution.
- Whether expected development milestones and spending plans were achieved; the filing provides no formal financial guidance.